Li Bin, Li Lei, Ren He
Department of Ultrasound Medicine, Beijing Aerospace General Hospital, Beijing, China.
Department of Interventional Radiology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao, 266042, Shandong, China.
J Gastrointest Cancer. 2025 Apr 17;56(1):101. doi: 10.1007/s12029-025-01222-y.
The choice between surgical resection (SR) and microwave ablation (MWA) as first-line treatments that prolong survival duration for colorectal liver oligometastases (CRLOM) remains controversial.
This study aimed to compare survival outcomes, therapeutic parameters, and safety between SR and MWA in patients with CRLOM.
From January 2012 to December 2022, we identified 1027 eligible patients with CRLOM who underwent either SR (n = 464) or MWA (n = 563) as hepatic local-region treatment. The cumulative 1-, 3-, 5-, and 8-year overall survival (OS) and progression-free survival (PFS) rates between the two modalities were compared using the Kaplan-Meier method with the log-rank test. The propensity score matching (PSM) method was used to improve the selective bias. Univariate and multivariate analyses of clinicopathological variables were conducted to identify risk factors affecting long-term survival.
After PSM, all baseline variables were balanced between the SR (n = 393) and MWA groups (n = 393). After a median follow-up of 39.8 months, no significant differences in the long-term survival outcomes were observed between the two groups (median OS time, MWA: 70.6 months vs. SR: 83.2 months; P = 0.124; median PFS time, MWA: 18.5 months vs. SR: 22.3 months; P = 0.680). PSM-adjusted analyses revealed similar results. The presence of 3-5 intrahepatic nodules (hazards ratio [HR] 1.65; 95% CI 1.31-2.06; P < 0.001) and SR (HR 1.28; 95% CI 1.11-1.69; P = 0.028) were independent prognostic risk factors for OS. A significant interaction effect of therapeutic modality and age, pathological differentiation, diameter, and number was observed (P = 0.039, 0.004, 0.031, and 0.032).
MWA offers comparable long-term survival benefits to SR for patients with CRLOM.
手术切除(SR)和微波消融(MWA)作为延长结直肠癌肝寡转移(CRLOM)患者生存时间的一线治疗方法,其选择仍存在争议。
本研究旨在比较CRLOM患者中SR和MWA的生存结局、治疗参数及安全性。
2012年1月至2022年12月,我们确定了1027例符合条件的CRLOM患者,他们接受了SR(n = 464)或MWA(n = 563)作为肝脏局部区域治疗。采用Kaplan-Meier法和对数秩检验比较两种治疗方式的累积1年、3年、5年和8年总生存(OS)率及无进展生存(PFS)率。采用倾向评分匹配(PSM)法以减少选择偏倚。对临床病理变量进行单因素和多因素分析,以确定影响长期生存的危险因素。
PSM后,SR组(n = 393)和MWA组(n = 393)的所有基线变量均达到平衡。中位随访39.8个月后,两组长期生存结局无显著差异(中位OS时间,MWA组:70.6个月 vs. SR组:83.2个月;P = 0.124;中位PFS时间,MWA组:18.5个月 vs. SR组:22.3个月;P = 0.680)。PSM调整分析显示了相似的结果。存在3 - 5个肝内结节(风险比[HR] 1.65;95%置信区间1.31 - 2.06;P < 0.001)和SR(HR 1.28;95%置信区间1.11 - 1.69;P = 0.028)是OS的独立预后危险因素。观察到治疗方式与年龄、病理分化、直径和数量之间存在显著的交互作用(P = 0.039, 0.004, 0.031和0.032)。
对于CRLOM患者,MWA与SR的长期生存获益相当。